Director at Janux Therapeutics (JANX) gets new RSUs and stock options

Rhea-AI Filing Summary

Janux Therapeutics director Vickie L. Capps received new equity awards. She was granted 5,500 restricted stock units, each convertible into one share of common stock, increasing her direct holdings to 79,598 shares. She also received options on 15,500 shares at an exercise price of $13.66 per share, vesting over 12 months and fully by the next annual stockholder meeting, subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider CAPPS VICKIE L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,500	$0.00	--
Grant/Award	Common Stock	5,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 15,500 shares (Direct, null); Common Stock — 79,598 shares (Direct, null)

Footnotes (1)

1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Key Figures

RSU grant size: 5,500 units Options granted: 15,500 shares Option exercise price: $13.66 per share +3 more

6 metrics

RSU grant size 5,500 units Restricted stock units awarded to director

Options granted 15,500 shares Stock options on common stock

Option exercise price $13.66 per share Strike price for new stock options

Shares held after grant 79,598 shares Common stock directly owned post-award

Option expiration date June 10, 2036 End of option exercise period

RSU vesting date June 11, 2027 Or earlier next annual stockholder meeting

Key Terms

restricted stock units ("RSUs"), contingent right, continuous service, Stock Option (right to buy), +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"each of which represents a contingent right to receive one share of the Issuer's common stock"

continuous service financial

"in each case, subject to the Reporting Person's continuous service on such date"

Stock Option (right to buy) financial

"Stock Option (right to buy) listed as a derivative security transaction"

vest in equal monthly installments financial

"The shares subject to the option will vest in equal monthly installments over the 12 months"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAPPS VICKIE L

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		5,500(1)	A	$0	79,598	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.66	06/11/2026		A		15,500		(2)	06/10/2036	Common Stock	15,500	$0	15,500	D

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

2. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

	/s/ James Pennington, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Janux Therapeutics (JANX) director Vickie L. Capps receive in this Form 4?

Vickie L. Capps received equity compensation consisting of 5,500 restricted stock units and stock options on 15,500 shares. Both awards relate to Janux Therapeutics common stock and were granted as part of her role as a director, not as open-market transactions.

How many Janux Therapeutics (JANX) shares does Vickie L. Capps hold after the grant?

After the grant, Vickie L. Capps directly holds 79,598 shares of Janux Therapeutics common stock. This figure reflects her updated ownership following the award of 5,500 restricted stock units reported in the Form 4 insider transaction filing.

What are the key terms of the RSU grant reported for JANX director Capps?

The 5,500 RSUs each represent a contingent right to one JANX common share. They will vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to Vickie L. Capps maintaining continuous service with Janux Therapeutics through that vesting date.

What are the terms of the Janux Therapeutics stock options granted to Vickie L. Capps?

Capps received options for 15,500 shares of Janux Therapeutics common stock at a $13.66 exercise price. These options vest in equal monthly installments over 12 months after June 11, 2026 and will be fully vested by the next annual stockholder meeting, subject to continued service.

Is the Janux Therapeutics (JANX) Form 4 a market purchase or sale of shares?

The Form 4 reflects compensation-related grants, not open-market trades. Vickie L. Capps acquired 5,500 RSUs and 15,500 stock options at no cash cost per share, consistent with equity awards typically granted to directors as part of their service.

When do the Janux Therapeutics stock options granted to Capps expire?

The stock options granted to Vickie L. Capps expire on June 10, 2036. She can exercise them at $13.66 per share once vested, subject to the vesting schedule and her continued service with Janux Therapeutics through the relevant vesting dates.